NEW YORK, May 5 (GenomeWeb News) -- Sirna Therapeutics has closed an $18.7 million private placement of its common stock to undisclosed institutional investors, the company said today.
The Boulder, Colo.-based RNAi developer sold 5.8 million of its common shares in the transaction.